Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative GroupAnna Sureda, E. Condé, Isidro Jarque et al.|Journal of Clinical Oncology|2001Cited by 233
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapseAnna Sureda, E. Condé, M. Constans et al.|Annals of Oncology|2005Cited by 220
Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative ProtocolIván Alvarez, Jorge Sierra, Anna Sureda et al.|Transplantation and Cellular Therapy|2006Cited by 142
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)Ramón García‐Sánz, Carmen Martı́nez, Anna Sureda et al.|Annals of Oncology|2019Cited by 129
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experienceJosé Rodríguez, E. Condé, Marı́a Dolores Caballero et al.|Annals of Oncology|2003Cited by 129